Four-channel asymmetric Real-Time PCR hybridization probe assay: A rapid pre-screening method for critical BCR-ABL kinase domain mutations

详细信息	查看全文 | 推荐本文 |

• 作者：Jordi Martinez-Serra^a ; ¹ ; ^{jorgej.martinez@ssib.es} ; Antonio Gutié ; rrez^a ; ¹ ; Toni F. Marcú ; s^a ; Simona Soverini^b ; Juan Carlos Amat^a ; Marí ; a Navarro-Palou^a ; Teresa Ros^a ; Teresa Bex^a ; Carmen Ballester^a ; Josep Miquel Bauç ; a^c ; Sara SanFelix^a ; André ; s Novo^a ; Carmen Vidal^d ; Carmen Santos^d ; Joan Besalduch^a
• 关键词：Real-Time ; PCR ; FRET ; Asymmetric ; BCR-ABL ; Kinase ; Imatinib ; Dasatinib ; Nilotinib ; Ponatinib
• 刊名：Clinical Biochemistry
• 出版年：2012
• 期刊代码：55_00099120
• 类别：med
• 出版时间：March, 2012
• 卷：45
• 期：4-5
• 页码：345-351
• 文件大小：955 K

摘要

Objectives

Within the laboratory protocols, used for the study of BCR-ABL resistance mutations in chronic myeloid leukemia patients treated with Imatinib, direct sequencing remains the reference method. Since the incidence of patients with a mutation-related loss of response is not very high, it is very useful in the routine laboratory to perform a fast pre-screening method.

Design and methods

With this in mind, we have designed a new technique, based on a single Real-Time FRET-based PCR, followed by a study of melting peaks. This new tool, developed in a LightCycler 2.0, combines four different fluorescence channels for the simultaneous detection, in a single close tube, of critical mutations within the ABL kinase domain.

Results

Assay evaluation performed on 33 samples, previously genotyped by sequentiation, resulted in full concordance of results.

Conclusions

This new methodology detects in a few steps the presence of critical mutations associated to Imatinib resistance.